Arbutus’ LNP Licensee Alnylam Announces Positive Phase 3 Results for LNP-Enabled Patisiran Program
Go back to Arbutus’ LNP Licensee Alnylam Announces Positive Phase 3 Results for LNP-Enabled Patisiran Program| (NASDAQ: ABUS) | Delayed: 4.51 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.51 | 52 Week High | $5.88 | |||
| Open | $4.51 | 52 Week Low | $2.65 | |||
| Day High | $4.51 | P/E | N/A | |||
| Day Low | $4.51 | EPS | $0.00 | |||
| Volume | 48 | |||||
| Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) | Delayed: 286.41 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $286.41 | 52 Week High | $109.10 | |||
| Open | $286.41 | 52 Week Low | $31.38 | |||
| Day High | $286.41 | P/E | N/A | |||
| Day Low | $286.41 | EPS | $-1.45 | |||
| Volume | 504 | |||||
